Literature DB >> 17595271

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer.

Maud M Geenen1, Mathilde C Cardous-Ubbink, Leontien C M Kremer, Cor van den Bos, Helena J H van der Pal, Richard C Heinen, Monique W M Jaspers, Caro C E Koning, Foppe Oldenburger, Nelia E Langeveld, Augustinus A M Hart, Piet J M Bakker, Huib N Caron, Flora E van Leeuwen.   

Abstract

CONTEXT: Improved survival of children with cancer has been accompanied by multiple treatment-related complications. However, most studies in survivors of childhood cancer focused on only 1 late effect.
OBJECTIVE: To assess the total burden of adverse health outcomes (clinical or subclinical disorders ["adverse events"]) following childhood cancer in a large cohort of childhood cancer survivors with long-term and complete medical follow-up. DESIGN, SETTING, AND POPULATION: Retrospective cohort study of 1362 five-year survivors of childhood cancer treated in a single institution in the Netherlands between 1966 and 1996. All survivors were invited to a late-effects clinic for medical assessment of adverse events. Adverse events occurring before January 2004 were graded for severity in a standardized manner. MAIN OUTCOME MEASURES: Treatment-specific prevalence of adverse events (according to severity) at end of follow-up and relative risk of high or severe burden of disease (> or =2 severe or > or =1 life-threatening or disabling adverse events) associated with various treatments.
RESULTS: Medical follow-up was complete for 94.3% of survivors (median follow-up, 17.0 years). The median attained age at end of follow-up was 24.4 years. Almost 75% of survivors had 1 or more adverse events, and 24.6% had 5 or more adverse events. Furthermore, 40% of survivors had at least 1 severe or life-threatening or disabling adverse event. A high or severe burden of adverse events was observed in 55% of survivors who received radiotherapy only and 15% of survivors treated with chemotherapy only, compared with 25% of survivors who had surgery only (adjusted relative risks, 2.18 [95% confidence interval, 1.62-2.95] and 0.65 [95% confidence interval, 0.46-0.90], respectively). A high or severe burden of adverse events was most often observed in survivors of bone tumors (64%) and least often in survivors of leukemia or Wilms tumor (12% each).
CONCLUSIONS: In young adulthood, a substantial proportion of childhood cancer survivors already has a high or severe burden of disease, particularly after radiotherapy. This underscores the need for lifelong risk-stratified medical surveillance of childhood cancer survivors.

Entities:  

Mesh:

Year:  2007        PMID: 17595271     DOI: 10.1001/jama.297.24.2705

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  228 in total

1.  Late effects and quality of life of childhood cancer survivors: Part 2. Impact of radiotherapy.

Authors:  Yasushi Ishida; Naoko Sakamoto; Kiyoko Kamibeppu; Naoko Kakee; Tsuyako Iwai; Shuichi Ozono; Naoko Maeda; Jun Okamura; Keiko Asami; Hiroko Inada; Misato Honda; Keizo Horibe
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

Review 2.  Collaborative Research in Childhood Cancer Survivorship: The Current Landscape.

Authors:  Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

3.  Barriers and Facilitators of Healthy Diet and Exercise Among Adolescent and Young Adult Cancer Survivors: Implications for Behavioral Interventions.

Authors:  Yelena P Wu; Jaehee Yi; Jessica McClellan; Jonghee Kim; Tian Tian; Bridget Grahmann; Anne C Kirchhoff; Avery Holton; Jennifer Wright
Journal:  J Adolesc Young Adult Oncol       Date:  2015-12       Impact factor: 2.223

4.  Editorial on the role of "Genetic mediators of neurocognitive outcome in survivors of childhood acute lymphoblastic leukemia".

Authors:  Birgit Burkhardt
Journal:  Transl Pediatr       Date:  2013-10

5.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

6.  Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer.

Authors:  Kevin C Oeffinger; Jennifer S Ford; Chaya S Moskowitz; Lisa R Diller; Melissa M Hudson; Joanne F Chou; Stephanie M Smith; Ann C Mertens; Tara O Henderson; Debra L Friedman; Wendy M Leisenring; Leslie L Robison
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

7.  Neurocognitive Consequences of Childhood Leukemia and Its Treatment.

Authors:  Ayşe Bozkurt Turhan; S Tülin Fidan; Coşkun Yarar; E Nazlı Sakallı; Zeynep Canan Özdemir; Özcan Bör
Journal:  Indian J Hematol Blood Transfus       Date:  2017-07-04       Impact factor: 0.900

Review 8.  Risk-based health monitoring of childhood cancer survivors: a report from the Children's Oncology Group.

Authors:  Susan B Nunez; Daniel A Mulrooney; Caroline Laverdiere; Melissa M Hudson
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

9.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Childhood cancer, endocrine disorders, and cohort studies.

Authors:  Kevin C Oeffinger; Charles A Sklar
Journal:  Lancet       Date:  2014-02-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.